Teva Pharmaceutical Industries Limited filed a Current Report on September 3, 2026, to recast historical segment information from its Annual Report for the year ended December 31, 2025, reflecting a change in how its U.S. distribution business, Anda, is reported.
Key Highlights
- Segment reclassification: Anda, Teva's U.S. distribution business, moved from the United States segment to Other Activities, effective January 1, 2026.
- Reporting alignment: The Company aligned its internal financial and segment reporting effective for the quarter ended March 31, 2026.
- Not a restatement: According to the filing, the recast "is not an amendment to, or a restatement of, the Original Report."
- No financial statement changes: Consolidated balance sheets, income statements, and cash flow statements from the Original Report remain unchanged.
- Exhibit 99.1 scope: The recast updates Business, MD&A, and Financial Statements sections of the Original Report solely for segment reporting changes.
- Signed by CFO: The filing was signed by Eli Kalif, Executive Vice President and Chief Financial Officer.
Teva Shifts Anda Distribution Business Out of Its U.S. Segment
Teva Pharmaceutical Industries Limited (NYSE:TEVA), an Israel-incorporated global pharmaceutical company, filed this Current Report to provide recast segment disclosures tied to a structural change in how it classifies Anda, its U.S. pharmaceutical distribution operation. According to the filing, beginning January 1, 2026, Anda is no longer reported under the Company's United States segment and is instead reported as part of Other Activities. The Company described the move as being "in alignment with Teva's Pivot to Growth strategy," which aims to strengthen focus on its biopharmaceutical business, growth engines, and innovation within the United States segment.
The filing specifies that Exhibit 99.1 contains recast versions of three sections from the Original Report: Part I Item 1 (Business), Part II Item 7 (Management's Discussion and Analysis), and Part II Item 8 (Financial Statements and Supplementary Data), including changes to Note 1 on significant accounting policies, Note 3 on revenue disaggregation, and Note 19 on segments. The filing states that changes are limited strictly to segment-related disclosures and their downstream impacts, and that no other disclosures in the Original Report have been modified.
The Company also noted that this Current Report "does not reflect changes or events occurring subsequent to the Original Report" and should be read together with both the Original Report and the Quarterly Reports on Form 10-Q for the periods ended March 31, 2026, and June 30, 2026. Kesselman and Kesselman, a member of PricewaterhouseCoopers International Ltd., provided an auditor consent included as Exhibit 23.1.
What Was Disclosed
Teva filed this Current Report to recast historical segment data from its fiscal year 2025 Annual Report, moving the Anda distribution business from the United States segment to Other Activities effective January 1, 2026, with no changes to consolidated financial statements.



Please wait processing your request...